TO IDENTIFY, EVALUATE, AND ANALYZE THE POSSIBLE DRUG-DRUG INTERACTIONS IN PATIENTS DIAGNOSED AS TYPE 2 DIABETES MELLITUS WITH HYPERTENSION IN A TERTIARY CARE TEACHING HOSPITAL

Authors

  • SUSHILKUMAR P LONDHE BAPUJI PHARMACY COLLEGE
  • ABRAHAM JOSEPH
  • JOSE JOHN
  • KIRAN PHILIP
  • LITHIN PHILIP

Abstract

Objective: To identify, evaluate, and analyze the possible drug-drug interactions (DDIs) in patients diagnosed as Type 2 diabetes mellitus with
hypertension in a tertiary care teaching hospital Davangere.
Methods: This prospective interventional study was conducted for a period of 6 months. Data were collected from patients who were prescribed with
at least one antidiabetic drug and at least one antihypertensive drug at the same time. Data were analyzed for DDIs by using software Micromedex and
other resources. Results were notified to the physicians for modification or alteration in the drug therapy.
Results: A total of 150 patients were analyzed out of which, 60.67% were male, and the rest 39.33% were female. In terms of interactions present,
95 (63.33%) prescriptions had one or more interactions. Antihypertensive drugs most frequently seen in prescriptions were diuretics (24.44%). Antidiabetic
drugs seen frequently prescribed are biguanides (34.36%). A total of 167 possible DDIs were obtained. Angiotensin-converting enzyme inhibitors were
most frequently involved antihypertensive drug in DDIs, with 60 of all possible DDIs identified. Insulin and biguanides were most frequently involved
antidiabetic drugs in DDIs, with 58 each of all possible DDIs identified. Most frequently interacting drug pair was insulin + metformin (n=19).
Conclusion: For every possible DDIs found in the prescription, the appropriate intervention was advised from the investigator's part as well as
provision for a physician to review and initiate modification of his choice.
Keywords: Hypertension, Possible drug-drug interaction, Type 2 diabetes mellitus.

 

Downloads

Download data is not yet available.

References

Zaman Huri H, Fun Wee H. Drug related problems in type 2 diabetes

patients with hypertension: A cross-sectional retrospective study. BMC

Endocr Disord 2013;13:2.

Parameshappa B, Rao VN, Gouda ST, Sen S, Chakraborty R, Basha AN,

et al. A study on drug-drug interaction between anti-hypertensive

drug (Propranolol) and anti-diabetic drug (Glipizide). Ann Biol Res

;1(3):35-40.

Triplitt C. Drug interaction of medications commonly used in diabetes.

Diabetes Spectr 2006;19(4):202-11.

Stults B, Jones RE. Management of hypertension in diabetes. Diabetes

Spectr 2006;19:25-31.

Cooper–DeHoff RM, Bird ST, Nichols GA, Delaney JA, Winterstein AG.

Antihypertensive drug class interactions and risk for incident diabetes:

A nested case-control study. J Am Heart Assoc 2013;2(3):e000125.

Karagiannis A, Tziomalos K, Pagourelias ED, Gossios TD, Athyros VG.

Effect of antihypertensive drug-associated diabetes on cardiovascular

risk. Hellenic J Cardiol 2010;51(3):195-9.

Wood AJ. Drug interactions in hypertension. Am Heart Assoc

;11(3):1-3.

Neto CV, Garcia PV, Helena ST. Possible pharmacological interactions

in hypertensive and/or diabetic elderly in family health units At

Blumenau (SC). Braz J Pharm Sci 2010;46(4):795-804.

Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension

in adult patients with diabetes. Diabetes Care 2002;25(1):134-47.

Arya SN. Hypertension in diabetic patients – Emerging trends. J Indian

Acad Clin Med 2003;4(2):96-102.

Whalen KL, Stewart RD. Pharmacologic management of hypertension

in patients with diabetes. Am Fam Physician 2008;78(11):1277-82.

Rafiei H, Arab M, Ranjbar H, Sepehrig G, Arab N, Amiri M. The

prevalence of potential drug-drug interactions in intensive care units.

Iran J Crit Care Nurs 2012;4(4):191-6.

Mateti U, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy S,

Ramachandran P. Drug-drug interactions in hospitalized cardiac

patients. J Young Pharm 2011;3(4):329-33.

Mallet L, Spinewine A, Huang A. The challenge of managing drug

interactions in elderly people. J Med 2007;320:185-91.

Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D,

Bozina N, Tomic S. Adverse drug reactions caused by drug-drug

interactions reported to Croatian Agency for Medicinal Products and

Medical Devices: A retrospective observational study. Croat Med J

;52(5):604-14.

Obreli Neto PR, Nobili A, Marusic S, Pilger D, Guidoni CM, Baldoni

Ade O, et al. Prevalence and predictors of potential drug-drug

interactions in the elderly: A cross-sectional study in the Brazilian

primary public health system. J Pharm Pharm Sci 2012;15(2):344-54.

Jimmy OD, Shobha R, Indira R, Ramjan S. Study of drug-drug

interactions in the medication charts in medicine wards at a tertiary care

hospital, Bangalore. Indian J Pharm Pract 2012;5(4):61-4.

Mahendra KB, Kumaraswamy M, Mahadevamma L. Incidence

and pattern of potential drug interactions of antimicrobial agents

in the Department of medicine in a tertiary care teaching hospital:

A prospective study. Asian J Pharm Clin Res 2011;4(2):31-6.

Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al.

A population-based study of the drug interaction between proton pump

inhibitors and clopidogrel. CMAJ 2009;180(7):713-8.

Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated

with length of stay and cost of hospitalization. J Pharm Pharm Sci

;12(3):266-72.

Reis AM, Cassiani SH. Prevalence of potential drug interactions in

patients in an intensive care unit of a university hospital in Brazil.

Clinics (Sao Paulo) 2011;66(1):9-15.

Sharma S, Chhetri HP, Alam K. A study of potential drug-drug

interactions among hospitalized cardiac patients in a teaching hospital

in Western Nepal. Indian J Pharmacol 2014;46(2):152-6.

Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions

between antithrombotic medications and the risk of gastrointestinal

bleeding. CMAJ 2007;177(4):347-51.

Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug

interactions and its associated factors in a Brazilian teaching hospital.

J Pharm Pharm Sci 2006;9(3):427-33.

Chelkeba L, Alemseged F, Bedada W. Assessment of potential

drug-drug interactions among outpatients receiving cardiovascular

medications at Jimma University Specialized Hospital, South West

Ethiopia. Int J Basic Clin Pharmacol 2013;2(2):114-52.

Richards TR, Tobe SW. Combining other antihypertensive drugs with

ß-blockers in hypertension: A focus on safety and tolerability. Can J

Cardiol 2014;30 5 Suppl: S42-6.

Tornio A, Niemi M, Neuvonen PJ, Backman JT. Drug interactions with

oral antidiabetic agents: Pharmacokinetic mechanisms and clinical

implications. Trends Pharmacol Sci 2012;33(6):312-22.

Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in

the treatment of type 2 diabetes mellitus: A clinical review with a focus

on dual therapy. Clin Ther 2003;25(12):2991-3026.

Devi JO, George KB, Cheriyan MH, Londhe SP, Vinay DM. To identify

and analyze potential drug-drug interactions from the medication charts

of medicine units of a tertiary care teaching hospital, Davangere. Int J

Pharm Res Sch (IJPRS) 2015;4(1):196-204.

Reimche L, Forster AJ, van Walraven C. Incidence and contributors

to potential drug-drug interactions in hospitalized patients. J Clin

Pharmacol 2011;51(7):1043-50.

Tripathi KD. Essentials of Medical Pharmacology. 6

ed. New Delhi:

Jaypee Brothers Medical Publishers; 2006.

Stockley IH. Stockley’s Drug Interactions. 8

th

th

ed. Great Britain:

Pharmaceutical Press; 2008.

Published

01-11-2015

How to Cite

P LONDHE, S., A. JOSEPH, J. JOHN, K. PHILIP, and L. PHILIP. “TO IDENTIFY, EVALUATE, AND ANALYZE THE POSSIBLE DRUG-DRUG INTERACTIONS IN PATIENTS DIAGNOSED AS TYPE 2 DIABETES MELLITUS WITH HYPERTENSION IN A TERTIARY CARE TEACHING HOSPITAL”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 6, Nov. 2015, pp. 169-74, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/8134.

Issue

Section

Original Article(s)